Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Collegium Pharmaceutical, Inc./ 10-K

Annual Report · 10-K

Collegium Pharmaceutical, Inc.

COLLNASDAQEQUITYCurrent

Annual Report

Filed Feb 22, 2024Accepted Feb 22, 2024, 4:03 PM ESTCIK 1267565Accession 0001558370-24-001526
View company →Permanent SEC source ↗
Share

Company context

Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.

Current securities

COLLNASDAQ · EQUITY · Current

Recent company filings

  1. SCHEDULE 13G - filed by INTEGRATED CORE STRATEGIES (US) LLC regarding COLLEGIUM PHARMACEUTICAL, INCAug 24, 2026
  2. Other EventsAug 13, 2026
  3. 10-Q filingAug 6, 2026
  4. Results of Operations and Financial Condition · Regulation FD DisclosureAug 6, 2026
  5. SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding COLLEGIUM PHARMACEUTICAL, INCJul 31, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.